tetano
Editor, Senior Moderator
Curr Opin Immunol. 2018 Apr 17;53:45-50. doi: 10.1016/j.coi.2018.04.002. [Epub ahead of print]
[h=1]Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?[/h] Tan J[SUP]1[/SUP], Asthagiri Arunkumar G[SUP]1[/SUP], Krammer F[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The development of a broadly protective or universal influenza virus vaccine is currently a public health priority worldwide. The vast majority of these efforts is exclusively focused on influenza A viruses. While influenza A viruses cause the majority of all influenza cases worldwide, influenza B viruses should not be ignored. Approximately 25% of all influenza cases are caused by influenza B viruses which circulate as two distinct B/Victoria/2/87-like and B/Yamagata/16/88-like lineages. In contrast to popular belief, influenza B cases frequently cause significant morbidity and mortality, especially in children. Similar to influenza A viruses, influenza B viruses drift antigenically and the influenza B components of current vaccines have to be reformulated almost on an annual basis. A broadly protective vaccine against influenza B viruses is therefore urgently needed. Here we review both broadly protective anti-influenza B antibodies as well as the sparse attempts to create a universal influenza B virus vaccine.
PMID: 29677684 DOI: 10.1016/j.coi.2018.04.002
[h=1]Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?[/h] Tan J[SUP]1[/SUP], Asthagiri Arunkumar G[SUP]1[/SUP], Krammer F[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The development of a broadly protective or universal influenza virus vaccine is currently a public health priority worldwide. The vast majority of these efforts is exclusively focused on influenza A viruses. While influenza A viruses cause the majority of all influenza cases worldwide, influenza B viruses should not be ignored. Approximately 25% of all influenza cases are caused by influenza B viruses which circulate as two distinct B/Victoria/2/87-like and B/Yamagata/16/88-like lineages. In contrast to popular belief, influenza B cases frequently cause significant morbidity and mortality, especially in children. Similar to influenza A viruses, influenza B viruses drift antigenically and the influenza B components of current vaccines have to be reformulated almost on an annual basis. A broadly protective vaccine against influenza B viruses is therefore urgently needed. Here we review both broadly protective anti-influenza B antibodies as well as the sparse attempts to create a universal influenza B virus vaccine.
PMID: 29677684 DOI: 10.1016/j.coi.2018.04.002